24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID
...ns. 908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX). The primary objective of CONTEXT is to assess antiretroviral response by measuring the time averaged change in viral load (vRNA) from baseline (AAUCMB) at...48-wk resistance data comparing GW433908 boosted & unboosted with nelfinavir
...). 908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX).In the SOLO study, no patients (0 percent) in the 908/r arm, out of 32 subjects experiencing virologic failure or with ongoing viral replication, had detec......ts. First phase II clinical results for amprenavir prodrug (VX-175): VX-175 could provide significant simplification of protease inhibitor-based therapy by potentially allowing dosing of just two or three pills, once or twice a day. Meet with a Vertex medical director or clinical investi...Extensive Phase II Data Of Amprenavir (141W94/VX-478) To Be Presented
...llowing key presentations: First results of amprenavir used in double protease inhibitor (PI)combinations... February 2 at 10:30AM. Extended results of amprenavir in combination with 1592, an experimentalreverse transcriptase inhibitor. This two-drug, twice dail...